Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
Become a Member | Sign in
Home>News>This Article

Life Technologies Acquires Advanced Microscopy Group

Published: Thursday, November 08, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
Acquisition provides Life Technologies a complete set of imaging products across range of functionality and price points.

Life Technologies Corporation announced the acquisition of Advanced Microscopy Group or AMG, a privately held developer of imaging systems for research microscopy incorporated as Westover Scientific, Inc.  The manufacturer of the FLoid® Cell Imaging Station currently sold by Life, AMG enables Life to expand its product line of cell imaging instrumentation, while leveraging its Molecular Probes® portfolio of fluorescent dyes and reagents.

The acquisition also provides new product development opportunities for both laboratory and portable imaging devices. Life Technologies' Molecular Probes® range of fluorescent dyes and probes are broadly used in the research market and constitute a natural complement to the EVOS® range of microscopes manufactured by AMG.

"Our acquisition of Advanced Microscopy Group brings together two leaders in the cell imaging field," said Peter Dansky, president of Molecular and Cell Biology at Life Technologies. "With AMG's demonstrated excellence in innovative microscopy instrumentation and the Molecular Probes line of market leading imaging reagents, we're now better able to serve our customers with a complete portfolio of integrated solutions for cell analysis optimized for performance and ease of use."

AMG has a portfolio of imaging instruments that spans basic to advanced microscopy. The EVOS® range of instruments improves ease of use by eliminating conventional eyepieces and replacing them with LCD screens. Two entry-level microscopes, EVOS® XL and EVOS® XL-Core, address the tissue culture market for routine monitoring of cell culture through measurements of cell density and morphology. The instruments are brightfield and phase contrast enabled and come with a range of magnification lens options. The EVOS®FL is a multi-color fluorescent microscope with brightfield/phase contrast capabilities and a range of objective options.

AMG also developed Life Technologies' FLoid® Cell Imaging Station, a platform that offers revolutionary ease of use for fluorescent microscopy. Introduced in late 2011, FLoid® was developed to be ideally suited for laboratories that are new to imaging or do not require the advanced features found in more expensive instruments. The addition of the EVOS® product line complements the FLoid® system by maintaining simplicity in the user experience, while providing advanced capabilities and automation that are necessary for some applications.

"We are excited that Life Technologies places high value on our EVOS line," said Steve Lytle, founder and president of AMG. "Ultimately, it is our customers who will benefit most from the breadth of the combined portfolios. It also uniquely positions Life in the cell imaging field and will serve as the foundation for the development of new applications and products."

The microscopy market size is estimated to be approximately $770 million. The acquisition of AMG is expected to be neutral to Life's 2012 earnings, accretive to 2013 earnings and accretive to the company's overall ROIC by 2015. The financial terms of the deal are not being disclosed. AMG's existing business will remain in Bothell, Washington, and will join Life Technologies' Flow Cytometry and Imaging business unit.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies Announces Third Quarter 2012 Results
Revenue for the third quarter was $911 million, a decrease of 1.9 percent over the $929 million reported for the third quarter of 2011. Excluding the impact of currency, revenue growth for the quarter was 1.4 percent compared to the same period of the prior year.
Monday, November 05, 2012
Scientific News
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
The Life Story of Stem Cells
A model analyses the development of stem cell numbers in the human body.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Tissue Engineers Recruit Cells to Make Their Own Strong Matrix
Extracellular matrix is the material that gives tissues their strength and stretch. It’s been hard to make well in the lab, but a Brown University team reports new success. The key was creating a culture environment that guided cells to make ECM themselves.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Artificial Kidney Research Gets A Boost
Development of a surgically implantable, artificial kidney — a promising alternative to kidney transplantation or dialysis for people with end-stage kidney disease — has received a $6 million boost.
Improving the Efficiency of Red Blood Cell Production
Study points to way of significantly reducing cost of laboratory-produced cells.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos